[Oligometastases of neuroendocrine tumors-extent of surgery]

Chirurg. 2018 Jul;89(7):516-522. doi: 10.1007/s00104-018-0644-z.
[Article in German]

Abstract

Neuroendocrine tumors (NETs) are rare neoplasms, which represent complex challenges in diagnosis and treatment. Even in the metastatic stage there are important differences in the type of tumor in comparison to gastrointestinal and pancreatic adenocarcinomas. Therefore, the disease courses are substantially different depending on the grade of differentiation. Even in the metastatic stage the 5‑year survival rates of G1 tumors is up to 83%. Approximately 20% of small intestine NETs additionally show hormone activity, which can compromise survival and the quality of life. For individual treatment decisions the special tumor biology of these tumors must be taken into consideration more so than for other tumor entities. Surgery always becomes important for these tumors when a R0 resection appears possible. Oligometastasis of the liver and the lymph drainage system can be meaningfully approached by surgical treatment. In selected patients with an isolated liver involvement, a liver transplantation can be considered; however, even tumor debulking can lead to improvement in the quality of life and survival, especially for hormone active tumors with a carcinoid syndrome which cannot be conservatively controlled. The aim of this review is to present the value of surgical treatment options in the case of (oligo)metastasized NETs.

Keywords: Liver metastases; Liver transplantation; Multimodal therapy; Peritoneal carcinomatosis; Preoperative management.

Publication types

  • Review

MeSH terms

  • Humans
  • Intestinal Neoplasms*
  • Liver Neoplasms* / secondary
  • Liver Neoplasms* / surgery
  • Liver Transplantation*
  • Malignant Carcinoid Syndrome*
  • Neuroendocrine Tumors* / pathology
  • Neuroendocrine Tumors* / surgery
  • Quality of Life